NO303598B1 - FremgangsmÕte med kvantitativ analyse som forutsier diabetisk tilstand - Google Patents
FremgangsmÕte med kvantitativ analyse som forutsier diabetisk tilstand Download PDFInfo
- Publication number
- NO303598B1 NO303598B1 NO913884A NO913884A NO303598B1 NO 303598 B1 NO303598 B1 NO 303598B1 NO 913884 A NO913884 A NO 913884A NO 913884 A NO913884 A NO 913884A NO 303598 B1 NO303598 B1 NO 303598B1
- Authority
- NO
- Norway
- Prior art keywords
- chiro
- inositol
- sample
- concentrations
- insulin resistance
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title claims description 15
- 238000000034 method Methods 0.000 title claims description 12
- 238000004445 quantitative analysis Methods 0.000 title description 5
- CDAISMWEOUEBRE-UHFFFAOYSA-N inositol Chemical compound OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims abstract description 82
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 39
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims abstract description 30
- 206010022489 Insulin Resistance Diseases 0.000 claims abstract description 26
- 102000004877 Insulin Human genes 0.000 claims abstract description 15
- 108090001061 Insulin Proteins 0.000 claims abstract description 15
- 229940125396 insulin Drugs 0.000 claims abstract description 15
- 210000002700 urine Anatomy 0.000 claims abstract description 15
- 210000002966 serum Anatomy 0.000 claims abstract description 14
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 7
- 238000004458 analytical method Methods 0.000 claims description 14
- 238000002965 ELISA Methods 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 230000003647 oxidation Effects 0.000 claims description 2
- 238000007254 oxidation reaction Methods 0.000 claims description 2
- 230000009467 reduction Effects 0.000 claims description 2
- 230000004520 agglutination Effects 0.000 claims 1
- 238000003018 immunoassay Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 238000003556 assay Methods 0.000 abstract description 4
- 238000012207 quantitative assay Methods 0.000 abstract description 3
- 238000012544 monitoring process Methods 0.000 abstract description 2
- 238000012216 screening Methods 0.000 abstract description 2
- 208000024891 symptom Diseases 0.000 abstract description 2
- 238000003745 diagnosis Methods 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 description 5
- CDAISMWEOUEBRE-LKPKBOIGSA-N 1D-chiro-inositol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O CDAISMWEOUEBRE-LKPKBOIGSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 108010093096 Immobilized Enzymes Proteins 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
- 229960000367 inositol Drugs 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 241000364051 Pima Species 0.000 description 1
- 238000007818 agglutination assay Methods 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 150000001450 anions Chemical group 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000010030 glucose lowering effect Effects 0.000 description 1
- 150000004001 inositols Chemical class 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000001699 lithographically induced self-assembly Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 238000001964 muscle biopsy Methods 0.000 description 1
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47695390A | 1990-02-08 | 1990-02-08 | |
| PCT/US1991/000655 WO1991012335A1 (en) | 1990-02-08 | 1991-02-06 | Quantitative analysis of chiroinositol as a diabetic condition predictor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO913884L NO913884L (no) | 1991-10-03 |
| NO913884D0 NO913884D0 (no) | 1991-10-03 |
| NO303598B1 true NO303598B1 (no) | 1998-08-03 |
Family
ID=23893914
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO913884A NO303598B1 (no) | 1990-02-08 | 1991-10-03 | FremgangsmÕte med kvantitativ analyse som forutsier diabetisk tilstand |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP0468031B1 (da) |
| JP (1) | JP3118458B2 (da) |
| KR (1) | KR0175314B1 (da) |
| AT (1) | ATE151464T1 (da) |
| AU (2) | AU651572B2 (da) |
| CA (1) | CA2051630A1 (da) |
| DE (1) | DE69125536T2 (da) |
| DK (1) | DK0468031T3 (da) |
| ES (1) | ES2101742T3 (da) |
| GR (1) | GR3023760T3 (da) |
| NO (1) | NO303598B1 (da) |
| WO (1) | WO1991012335A1 (da) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5525526A (en) * | 1994-02-02 | 1996-06-11 | The University Of Virginia Patent Foundation | Immunoassay for inositols |
| US5550166A (en) * | 1995-03-17 | 1996-08-27 | Ostlund; Richard E. | Pinitol and derivatives thereof for the treatment of metabolic disorders |
| WO1998042863A1 (fr) * | 1997-03-26 | 1998-10-01 | Asahi Kasei Kogyo Kabushiki Kaisha | Procede hautement sensible de dosage du chiro-inositol et compositions destinees au dosage |
| CA2374269C (en) | 1999-05-20 | 2007-04-24 | Humanetics Corporation | Stimulating transport of glucose into animal tissue by the administration of pinitol |
| JP4602577B2 (ja) | 2001-03-15 | 2010-12-22 | 積水メディカル株式会社 | 前糖尿病状態のスクリーニング方法及びスクリーニング用試薬 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69024348T2 (de) * | 1989-03-08 | 1996-08-14 | Univ Virginia | Verfahren zum nachweis des diabetischen zustandes |
-
1991
- 1991-02-06 JP JP03504483A patent/JP3118458B2/ja not_active Expired - Fee Related
- 1991-02-06 DE DE69125536T patent/DE69125536T2/de not_active Expired - Fee Related
- 1991-02-06 AU AU72531/91A patent/AU651572B2/en not_active Ceased
- 1991-02-06 DK DK91904260.6T patent/DK0468031T3/da active
- 1991-02-06 ES ES91904260T patent/ES2101742T3/es not_active Expired - Lifetime
- 1991-02-06 EP EP91904260A patent/EP0468031B1/en not_active Expired - Lifetime
- 1991-02-06 CA CA002051630A patent/CA2051630A1/en not_active Abandoned
- 1991-02-06 WO PCT/US1991/000655 patent/WO1991012335A1/en active IP Right Grant
- 1991-02-06 KR KR1019910701268A patent/KR0175314B1/ko not_active IP Right Cessation
- 1991-02-06 AT AT91904260T patent/ATE151464T1/de not_active IP Right Cessation
- 1991-10-03 NO NO913884A patent/NO303598B1/no unknown
-
1994
- 1994-08-23 AU AU71410/94A patent/AU662268B2/en not_active Ceased
-
1997
- 1997-06-11 GR GR970401404T patent/GR3023760T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GR3023760T3 (en) | 1997-09-30 |
| CA2051630A1 (en) | 1991-08-09 |
| ATE151464T1 (de) | 1997-04-15 |
| EP0468031B1 (en) | 1997-04-09 |
| DE69125536T2 (de) | 1997-07-17 |
| AU662268B2 (en) | 1995-08-24 |
| AU7141094A (en) | 1994-11-24 |
| KR0175314B1 (ko) | 1999-02-01 |
| WO1991012335A1 (en) | 1991-08-22 |
| JP3118458B2 (ja) | 2000-12-18 |
| AU7253191A (en) | 1991-09-03 |
| DK0468031T3 (da) | 1997-05-12 |
| ES2101742T3 (es) | 1997-07-16 |
| NO913884L (no) | 1991-10-03 |
| KR920701472A (ko) | 1992-08-11 |
| EP0468031A1 (en) | 1992-01-29 |
| EP0468031A4 (en) | 1991-11-27 |
| DE69125536D1 (de) | 1997-05-15 |
| NO913884D0 (no) | 1991-10-03 |
| AU651572B2 (en) | 1994-07-28 |
| JPH04505218A (ja) | 1992-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MAuNsELL et al. | Routine isotope-dilution liquid chromatography–tandem mass spectrometry assay for simultaneous measurement of the 25-hydroxy metabolites of vitamins D2 and D3 | |
| EP2005189B1 (en) | MEANS AND METHOD FOR DIAGNOSING DIABETES type II | |
| Kiernan et al. | Comparative phenotypic analyses of human plasma and urinary retinol binding protein using mass spectrometric immunoassay | |
| WO2007112055A2 (en) | Apolipoprotein fingerprinting technique | |
| US5183764A (en) | Quantitative analysis for diabetic condition predictor involving chiro-inositol | |
| Vasikaran et al. | Intra-individual variation in fasting urinary calcium-and hydroxyproline-creatinine ratios measured in metabolic bone clinic patients as both outpatients and inpatients | |
| NO303598B1 (no) | FremgangsmÕte med kvantitativ analyse som forutsier diabetisk tilstand | |
| JP2014517300A (ja) | 多発性硬化症を診断する方法 | |
| US5427956A (en) | Quantitative analysis for diabetic condition predictor | |
| EP2059809A1 (en) | Means and method for diagnosing hemolytic anemia | |
| Witting et al. | Evaluation of a new specific analysis of urinary delta-aminolevulinic acid in man | |
| Namba et al. | A new method of quantitating serum and urinary levels of 1, 5-anhydroglucitol in insulin-dependent diabetes mellitus | |
| JPH04504001A (ja) | 糖尿病状態のスクリーニング法 | |
| KR101872586B1 (ko) | 비만 또는 비만 합병증의 예측 또는 진단마커 | |
| KONDO et al. | Direct injection method for quantitation of δ-aminolevulinic acid in urine by high-performance liquid chromatography | |
| CN114264767B (zh) | 用于糖尿病诊断的生物标志物及其用途 | |
| CN117420245A (zh) | 一种人干血斑神经酰胺的检测方法及用于检测神经酰胺的试剂盒 | |
| Grkovic et al. | Urinary catecholamine metabolites: Capillary gas chromatography method and experience with 12 cases of neuroblastoma | |
| Kaur et al. | COMMON ANTIDEPRESSANTS IN TOXICOLOGICAL MATRICES: A REVIEW | |
| CN114544826A (zh) | 检测血浆中组氨酸的试剂在制备抑郁症检测试剂盒中的用途 | |
| Craft | Innovative non or minimally-invasive technologies for monitoring health and nutritional status in mothers and young children | |
| Savory et al. | Use of High Resolution GC/MS for Obtaining Accuracy in Lipid Measurements | |
| KAJIWARA | Direct Injection Method for Quantitation of 5-Aminolevulinic Acid in Urine by High-Performance Liquid | |
| WO1994008044A1 (en) | Screening method for diabetic condition | |
| 近藤雅雄 et al. | Direct Injection Method for Quantitation of. DELTA.-Aminolevulinic Acid in Urine by High-Performance Liquid Chromatography. |